332 related articles for article (PubMed ID: 21790905)
1. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction.
Levran O; Peles E; Hamon S; Randesi M; Adelson M; Kreek MJ
Addict Biol; 2013 Jul; 18(4):709-16. PubMed ID: 21790905
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics biomarkers for personalized methadone maintenance treatment: The mechanism and its potential use.
Ramli FF
Bosn J Basic Med Sci; 2021 Apr; 21(2):145-154. PubMed ID: 32841585
[TBL] [Abstract][Full Text] [Related]
3. Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study.
Dobrinas M; Crettol S; Oneda B; Lahyani R; Rotger M; Choong E; Lubomirov R; Csajka C; Eap CB
Pharmacogenet Genomics; 2013 Feb; 23(2):84-93. PubMed ID: 23249875
[TBL] [Abstract][Full Text] [Related]
4. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokkar M; Gothuey I; Hämmig R; Monnat M; Hüttemann H; Baumann P; Eap CB
Clin Pharmacol Ther; 2005 Dec; 78(6):593-604. PubMed ID: 16338275
[TBL] [Abstract][Full Text] [Related]
5. Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis.
Dennis BB; Bawor M; Thabane L; Sohani Z; Samaan Z
PLoS One; 2014; 9(1):e86114. PubMed ID: 24489693
[TBL] [Abstract][Full Text] [Related]
6. PXR polymorphisms interacted with CYP2B6 polymorphisms on methadone metabolites.
Tsai HJ; Wang SC; Tian JN; Chang TK; Ho IK; Hsiao CF; Chen CH; Tan HK; Lin L; Wu CS; Su LW; Huang CL; Yang YH; Liu ML; Lin KM; Liu YL
J Clin Psychopharmacol; 2013 Feb; 33(1):137-40. PubMed ID: 23288240
[No Abstract] [Full Text] [Related]
7. Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity.
Mouly S; Bloch V; Peoc'h K; Houze P; Labat L; Ksouda K; Simoneau G; Declèves X; Bergmann JF; Scherrmann JM; Laplanche JL; Lepine JP; Vorspan F
Br J Clin Pharmacol; 2015 Jun; 79(6):967-77. PubMed ID: 25556837
[TBL] [Abstract][Full Text] [Related]
8. Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients.
Hung CC; Chiou MH; Huang BH; Hsieh YW; Hsieh TJ; Huang CL; Lane HY
Pharmacogenomics; 2011 Nov; 12(11):1525-33. PubMed ID: 21902500
[TBL] [Abstract][Full Text] [Related]
9. Relationship between CYP2B6*6 and cold pressor pain sensitivity in opioid dependent patients on methadone maintenance therapy (MMT).
Zahari Z; Lee CS; Ibrahim MA; Musa N; Mohd Yasin MA; Lee YY; Tan SC; Mohamad N; Ismail R
Drug Alcohol Depend; 2016 Aug; 165():143-50. PubMed ID: 27289271
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic evidence to support clinical decision making for peripartum methadone treatment.
Bogen DL; Perel JM; Helsel JC; Hanusa BH; Romkes M; Nukui T; Friedman CR; Wisner KL
Psychopharmacology (Berl); 2013 Jan; 225(2):441-51. PubMed ID: 22926004
[TBL] [Abstract][Full Text] [Related]
11. Interindividual variability in the prevalence of OPRM1 and CYP2B6 gene variations may identify drug-susceptible populations.
Bunten H; Liang WJ; Pounder DJ; Seneviratne C; Osselton D
J Anal Toxicol; 2011 Sep; 35(7):431-7. PubMed ID: 21871151
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.
Sukasem C; Cressey TR; Prapaithong P; Tawon Y; Pasomsub E; Srichunrusami C; Jantararoungtong T; Lallement M; Chantratita W
Br J Clin Pharmacol; 2012 Dec; 74(6):1005-12. PubMed ID: 22471906
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese.
Guan S; Huang M; Chan E; Chen X; Duan W; Zhou SF
Eur J Pharm Sci; 2006 Sep; 29(1):14-21. PubMed ID: 16815693
[TBL] [Abstract][Full Text] [Related]
14. Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics.
Ahmad T; Valentovic MA; Rankin GO
Biochem Pharmacol; 2018 Jul; 153():196-204. PubMed ID: 29458047
[TBL] [Abstract][Full Text] [Related]
15. Role of cytochrome P4502B6 in methadone metabolism and clearance.
Kharasch ED; Stubbert K
J Clin Pharmacol; 2013 Mar; 53(3):305-13. PubMed ID: 23361846
[TBL] [Abstract][Full Text] [Related]
16. Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance.
Rohrbacher M; Kirchhof A; Geisslinger G; Lötsch J
Pharmacogenomics; 2006 Oct; 7(7):995-1002. PubMed ID: 17054410
[TBL] [Abstract][Full Text] [Related]
17. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer.
Wang SC; Ho IK; Tsou HH; Tian JN; Hsiao CF; Chen CH; Tan HK; Lin L; Wu CS; Su LW; Huang CL; Yang YH; Liu ML; Lin KM; Chen CY; Liu SC; Wu HY; Chan HW; Tsai MH; Lin PS; Liu YL
J Clin Psychopharmacol; 2011 Aug; 31(4):463-9. PubMed ID: 21694616
[TBL] [Abstract][Full Text] [Related]
18. Implications of OPRM1 and CYP2B6 variants on treatment outcomes in methadone-maintained patients in Ontario: Exploring sex differences.
Chawar C; Hillmer A; Lamri A; Kapczinski F; Thabane L; Pare G; Samaan Z
PLoS One; 2021; 16(12):e0261201. PubMed ID: 34910759
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz.
Wang J; Sönnerborg A; Rane A; Josephson F; Lundgren S; Ståhle L; Ingelman-Sundberg M
Pharmacogenet Genomics; 2006 Mar; 16(3):191-8. PubMed ID: 16495778
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population: identification of novel variant CYP2B6 alleles.
Restrepo JG; Martínez C; García-Agúndez A; Gaviria E; Laguna JJ; García-Martín E; Agúndez JA
Pharmacogenet Genomics; 2011 Dec; 21(12):773-8. PubMed ID: 21886015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
